Brought to you by 
CANbridge gets rights to Aveo's mAb AV203; deal terminated
15 Mar 2021
Executive Summary
Aveo Pharmaceuticals Inc. (also known as Aveo Oncology) granted CANbridge Life Sciences Ltd. exclusive rights to develop and sell its anticancer monoclonal antibody AV203 worldwide excluding the US, Canada, and Mexico. Biogen Idec previously held an option to the project under a 2009 deal, but waived its option in 2014.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CANbridge gets rights to Aveo's mAb AV203; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice